Phase I Open-labeled Trial of Gemcitabine and Dasatinib in Advanced Solid Tumors.

Trial Profile

Phase I Open-labeled Trial of Gemcitabine and Dasatinib in Advanced Solid Tumors.

Completed
Phase of Trial: Phase I

Latest Information Update: 03 Apr 2013

At a glance

  • Drugs Dasatinib (Primary) ; Gemcitabine
  • Indications Solid tumours
  • Focus Adverse reactions; Biomarker
  • Most Recent Events

    • 01 Feb 2013 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
    • 15 Dec 2011 Planned end date changed from 1 Jan 2012 to 1 Jan 2014 as reported by ClinicalTrials.gov.
    • 24 Mar 2011 Planned end date changed from 1 Jan 2011 to 1 Jan 2012 as reported by ClinicalTrials.gov
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top